Related Experiment Videos
Arimidex: a potent and selective fourth-generation aromatase inhibitor
P V Plourde1, M Dyroff, M Dukes
1Zeneca Pharmaceuticals Group, Zeneca Inc., Wilmington, Delaware 19897.
Breast Cancer Research and Treatment
|January 1, 1994
Summary
Arimidex, an aromatase inhibitor, effectively treats advanced breast cancer in postmenopausal women by selectively blocking estrogen production. It demonstrates a favorable safety profile and pharmacokinetic properties in both animal and human studies.
Area of Science:
- Pharmacology
- Oncology
- Endocrinology
Background:
- Arimidex (anastrozole) is an investigational aromatase inhibitor for postmenopausal women with advanced breast cancer.
- Understanding its pharmacology is crucial for evaluating its therapeutic potential.
Purpose of the Study:
- To determine the pharmacology, pharmacodynamics, pharmacokinetics, and safety of Arimidex in animal models and human subjects.
- To assess the selective inhibition of aromatase and its effects on steroid hormone biosynthesis.
Main Methods:
- Pharmacological studies in animals to assess selectivity and activity.
- Pharmacokinetic and pharmacodynamic assessments in humans following single and multiple oral doses of Arimidex.
- Evaluation of effects on cortisol and aldosterone biosynthesis enzymes.
Main Results:
- Arimidex demonstrated potent and selective aromatase inhibition in animals, with rapid absorption and metabolism.
- In humans, Arimidex effectively suppressed estradiol levels and showed dose-proportional plasma concentrations.
- No clinically significant effects on cortisol and aldosterone biosynthesis enzymes were observed; Arimidex was well tolerated.
Conclusions:
- Arimidex is a well-tolerated, potent, and selective aromatase inhibitor with favorable pharmacokinetic properties.
- Its ability to suppress estradiol makes it a promising treatment for postmenopausal women with advanced breast cancer, warranting further Phase III evaluation.